Clinical DevelopmentLast reviewed April 2026

Primary Endpoint(Primary Endpoint)

The main outcome measure of a clinical trial, selected before the trial begins and used as the primary basis for the trial's conclusion about efficacy.

Usage Examples

The primary endpoint was progression-free survival at 12 months, powered for a hazard ratio of 0.67.
A patient-reported primary endpoint measured symptom improvement using the validated scale.

What is Primary Endpoint?

The primary endpoint is the outcome measure a clinical trial is designed to answer — the one that drives sample size calculation, statistical testing, and regulatory decision about efficacy. It must be pre-specified in the protocol and Statistical Analysis Plan before database lock, with a clear operational definition, measurement method, timing, and analysis approach.

Primary endpoints can be clinical (survival, symptom improvement, time to event), biomarker-based (objective response rate, progression-free survival, blood pressure), or patient-reported (pain, functional status, quality of life). Regulatory acceptance depends on the endpoint's clinical meaningfulness and its relationship to patient benefit. FDA and EMA expect endpoints to be validated; surrogate endpoints require additional justification and typically support accelerated approval pathways pending confirmatory evidence.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside ICH E9, ICH E10, FDA ACCELERATED APPROVAL.

FDAEMAPMDA

When This Matters

The primary endpoint was progression-free survival at 12 months, powered for a hazard ratio of 0.67.
A patient-reported primary endpoint measured symptom improvement using the validated scale.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

ICH E9ICH E10FDA ACCELERATED APPROVAL

Frequently Asked Questions

Yes, through co-primary or composite endpoints. Co-primary endpoints require all primary analyses to succeed with appropriate multiplicity control. Composite endpoints combine multiple events into one endpoint (e.g., major adverse cardiac events = death + MI + stroke). Both require pre-specification and careful statistical handling.

Primary: the main hypothesis, drives sample size, regulatory approval depends on it. Secondary: additional outcomes evaluated with hierarchical or gatekeeping methods, support label claims but don't drive primary approval. Exploratory endpoints are hypothesis-generating without formal statistical testing.

Generally no, and any change requires rigorous justification and pre-database-lock documentation. Changes after data lock or unblinding typically invalidate regulatory support for the trial. Protocol amendments changing primary endpoint are a significant regulatory red flag.